Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 320
- Registration Number
- NCT03776032
Maintenance Treatment of Renal Anemia in Dialysis Subjects
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 229
- Registration Number
- NCT03543657
- Locations
- 🇯🇵
Chibune Clinic, Osaka, Japan
🇯🇵Maruko Central Hospital, Ueda, Nagano, Japan
🇯🇵Houshikai Kano hospital, Kasuya-gun, Fukuoka, Japan
Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)
- Conditions
- Interventions
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT03446612
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 323
- Registration Number
- NCT03439137
- Locations
- 🇯🇵
Research site, Yamagata, Japan
A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 162
- Registration Number
- NCT03350321
- Locations
- 🇯🇵
Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, Japan
🇯🇵St.Mary's Hospital, Kurume, Fukuoka, Japan
🇯🇵Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan
A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 164
- Registration Number
- NCT03350347
- Locations
- 🇯🇵
Matsunami Health Promotion Clinic, Hashima-gun, Gifu, Japan
🇯🇵Mazda Hospital of Mazda Motor Corporation, Aki-gun, Hiroshima, Japan
🇯🇵Higashihiroshima Medical Center, Higashihiroshima, Hiroshima, Japan
Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
- Conditions
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 304
- Registration Number
- NCT03329196
- Locations
- 🇯🇵
Research site, Yamanashi, Japan
Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2017-08-08
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Akebia Therapeutics
- Registration Number
- NCT03242967
- Locations
- 🇺🇸
Research Site, Northridge, California, United States
Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration
- Conditions
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 80
- Registration Number
- NCT03171818
- Locations
- 🇳🇱
Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht, Netherlands
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- NICHD Neonatal Research Network
- Target Recruit Count
- 650
- Registration Number
- NCT03169881
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.